CRISPR Therapeutics (CRSP) Projected to Post Quarterly Earnings on Wednesday

CRISPR Therapeutics (NASDAQ:CRSP) is expected to announce its Q1 2025 earnings results before the market opens on Wednesday, May 14th. Analysts expect CRISPR Therapeutics to post earnings of ($1.26) per share for the quarter.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. During the same period in the previous year, the firm earned ($1.43) EPS. The company’s quarterly revenue was up 71.6% compared to the same quarter last year. On average, analysts expect CRISPR Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

CRISPR Therapeutics Price Performance

CRSP opened at $37.59 on Tuesday. The stock’s 50 day simple moving average is $38.03 and its 200 day simple moving average is $42.64. The firm has a market cap of $3.25 billion, a price-to-earnings ratio of -8.60 and a beta of 1.88. CRISPR Therapeutics has a 1 year low of $30.04 and a 1 year high of $67.88.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $55.20, for a total value of $1,013,472.00. Following the sale, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. This represents a 9.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Julianne Bruno sold 1,198 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $50,819.16. Following the transaction, the chief operating officer now directly owns 8,263 shares of the company’s stock, valued at $350,516.46. This represents a 12.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,381 shares of company stock worth $1,608,243 over the last ninety days. 4.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on CRSP shares. Evercore ISI upgraded shares of CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and raised their target price for the stock from $60.00 to $99.00 in a report on Friday, February 14th. TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price target for the company in a research report on Wednesday, February 12th. Barclays decreased their price objective on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an “equal weight” rating on the stock in a research report on Friday. Morgan Stanley increased their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a report on Friday, February 14th. Finally, Needham & Company LLC cut their target price on CRISPR Therapeutics from $84.00 to $81.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, CRISPR Therapeutics currently has an average rating of “Hold” and an average price target of $71.75.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.